Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 60.06 [6][4]. Core Views - The company is positioned as a "healthcare enterprise driven by both consumption and medical sectors," with its brands "Winner" and "Purcotton" gaining influence. The consumption segment is expected to maintain growth momentum despite short-term fluctuations due to public sentiment events, while the medical segment is anticipated to recover due to both internal and external growth drivers [1][3]. - The company has shown strong performance in its core product categories, particularly during the 618 shopping festival, with significant sales growth in key items such as facial towels and baby products [2][3]. Summary by Sections Consumption Segment - In Q1 2025, the consumption segment achieved revenue of RMB 1.34 billion, representing a year-on-year increase of 28.8%. Although Q2 revenue growth is expected to slow due to industry sentiment issues, core categories continue to perform well. The company has implemented product innovation and precise marketing strategies, leading to significant sales in e-commerce platforms [2][3]. - The marketing strategy has focused on product safety and brand recognition, particularly in the sanitary napkin category, which is expected to see continued growth alongside innovations in adult underwear and cotton soft towels [3][4]. Medical Segment - The medical segment is benefiting from ongoing product innovation and channel expansion, with a focus on domestic hospital channels and consumer medical channels. The acquisition of GRI is expected to enhance export capabilities due to its global production capacity [3][4]. Financial Forecast and Valuation - The company is projected to achieve net profits of RMB 1.061 billion, RMB 1.301 billion, and RMB 1.589 billion for the years 2025, 2026, and 2027, respectively, with corresponding EPS of RMB 1.82, RMB 2.23, and RMB 2.73. The report maintains a target PE of 33 times for 2025, reflecting the dual growth drivers of consumption and medical sectors [4][10].

Group 1: Company Overview - Steady Medical Group, founded in 1991, has evolved into a health enterprise focusing on medical and consumer sectors, listed on the Shenzhen Stock Exchange in 2020 [13] - The company aims to "protect health, care for life, and protect the environment" with its main brands being "Winner Medical" and "Purcotton" [13] Group 2: Annual Performance Review - In 2024, the company achieved a total revenue of 89.8 billion CNY, a 9.7% increase from 2023's 81.9 billion CNY [18] - Excluding infection protection product revenue, the adjusted revenue was 86.2 billion CNY, reflecting an 18.6% year-on-year growth [18] - The revenue structure for 2024 was 43% from medical consumables and 56% from consumer products [18] Group 3: Profitability - The net profit attributable to shareholders reached 7.0 billion CNY, a 19.8% increase compared to 2023 [21] - The net profit margin improved to 7.7%, up 0.7 percentage points from the previous year [21] - The gross profit margin for 2024 was 47.3%, indicating a stable profitability trend [20] Group 4: Asset Quality and R&D Investment - Total assets at the end of 2024 were 184 billion CNY, a 7.5% increase from the previous year [26] - The asset-liability ratio stood at 35.4%, maintaining a low level [26] - The company emphasized R&D, with a steady increase in the number of patents and medical product registrations [26] Group 5: Shareholder Returns - The proposed cash dividend for 2024 is 3.8 billion CNY, representing 54% of the net profit [30] - Cumulative cash dividends since listing amount to 26.1 billion CNY, accounting for 93% of the net proceeds from the IPO [30] Group 6: Medical Consumables Business - The medical segment generated 39.1 billion CNY in revenue for 2024, showing resilience despite a high base from infection protection products [34] - Excluding infection protection, the medical consumables revenue was 35.5 billion CNY, a 20.4% increase year-on-year [34] - Core categories such as high-end dressings and surgical consumables saw revenue growth exceeding 30% [34] Group 7: Consumer Products Business - The consumer segment, led by Purcotton, achieved 49.9 billion CNY in revenue, a 17.1% increase from 2023 [43] - Online sales contributed 62% of the revenue, while offline stores accounted for 30% [46] - The company added 92 new offline stores in 2024, bringing the total to 487 [46] Group 8: Q1 2025 Performance Overview - In Q1 2025, total revenue reached 26.1 billion CNY, a 36.5% increase year-on-year [53] - The medical business revenue for Q1 2025 was 12.5 billion CNY, up 46.3% [54] - The consumer business generated 13.4 billion CNY, reflecting a 28.8% growth [54]